MMP2 and corneal disorder: MSCs therapy in corneal disease inhibits infiltration of immune cells such as CD68+ macrophages and decreases pro-inflammatory cytokines, such as IL-2, IL-17, VEGF and matrix metallopeptidase 2 (MMP2).